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Introduction
The SARS COV2 and other SARS viruses employ a heavily glycosy-
lated spike S protein (Watanabe et al. 2020; Shajahan et al. 2020a) to
bind to the ACE2 cellular receptor, also heavily glycosylated (Shaja-
han et al. 2020b), on host cells. Historically, there is abundant infor-
mation of glycosylation inhibitors for antiviral activity to stimulate
their investigation for COVID19 treatment. While there are certain
to be side effects by interfering systematically with glycosylation, a
short-term dose of primers, decoys or glycosylation inhibitors might
be sufficient to stop or slow the COVID19 infection cycle with mini-
mal or temporary side effects. For example, castanospermine deriva-
tive celgosivir (6-O-butanoylcastanospermine) (Sels et al. 1999) and
Miglitol, Miglustat (N-butyl −1-deoxynojirimycin) (Campo et al.
2013; Zamoner et al. 2019) are already FDA approved for type 2
diabetes and Gaucher’s disease (Rosenbloom and Weinreb 2013),
passing safety and effectivity phases. This article is to stimulate
repurpose testing of these already-approved compounds and others
for COVID19 therapeutics.
Previously reported efficacy of antiviral activities
Copious literature suggests that glycosylation inhibitors are potent
antivirals for enveloped viruses with a coat or spike protein. In the
1970s and 1980s, a number of investigators examined interference
with glycan synthesis on viral coat proteins as a mode for viral
inhibition. Compans showed in 1971, D-glucosamine and 2-deoxy-
D-glucose inhibited glycoprotein maturation in Sindbis virus (Com-
pans 1971). Several other studies used these two compounds for
inhibition of Semliki Forest virus (Kaluza et al. 1972), enveloped
RNA viruses (Kaluza et al. 1973), Influenza (Klenk et al. 1972), VSV,
Newcastle disease (Scholtissek et al. 1974) and enveloped viruses in
general (Scholtissek et al. 1975). In 1973, Okayama et al. showed
that ß-xylosides could stimulate free GAG chains and inhibit GAG
formation on proteoglycan core proteins (Okayama et al. 1973).
Later, a number of researchers showed that GAGs were important as
cellular receptors in HSV and HCV and that ß-xylosides could inhibit
viral infectivity by sidetracking GAG synthesis to soluble saccharides
(see below).
Schwartz reported, in 1974, tunicamycin inhibition of glycosy-
lation of influenza virus hemagglutinin (Schwartz et al. 1974) and
in 1976 showed that tunicamycin, which inhibits the formation of
N-acetylglucosamine-lipid intermediates in N-linked glycan synthesis
(Lennarz 1975), suppressed glycoprotein synthesis in Semliki Forest,
influenza and avian sarcoma virus (Schwarz et al. 1976). Kornfeld
et al. (1977) examined the effect of tunicamycin (Leavitt et al. 1977a)
on growth of Sindbis and VSV in BHK cells and found at 500 ng/ml,
99.9% inhibition of replication without detection of non-infectious
particles (Leavitt et al. 1977b). Viral proteins were synthesized, but
glycoproteins were under-glycosylated (Leavitt et al. 1977b) and
temperature sensitive (Gibson et al. 1979). Their conclusion was that
in enveloped viruses, glycosylation was essential for normal viral
particle assembly. Morrison et al. (1978) found that tunicamycin had
no effect on glycoprotein attachment to intracellular membranes or
protein transport to the endoplasmic reticulum lumen, but instead
prevented glycoprotein migration from the rough to smooth. Korn-
feld et al. (1979) found that VSV non-glycosylated glycoprotein
underwent intracellular aggregation upon tunicamycin treatment
(Gibson et al. 1979), an indication of improper folding or exposure
of hydrophobic peptide due to pauciglycosylation. Diggelman (1979)
showed biosynthesis of an unglycosylated envelope glycoprotein of
Rous sarcoma virus in the presence of tunicamycin. Pizer et al.
(1980) showed that tunicamycin inhibited production of infectious
herpes simplex virus-1 (HSV1). Blocking addition of carbohydrate to
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of proteins, postulated due to degradation of unglycosylated polypep-
tides. They concluded that the glycans either stabilize the envelope
proteins or provide proper structure for processing of the proteins
necessary for infectivity. Stallcup and Fields (1981) inhibited measles
virus with tunicamycin (24).
Holmes et al. (1981) showed that a corona virus, mouse hep-
atitis virus, MHV, had a glycoprotein E1 glycosylated normally in
the presence of tunicamycin. This indicated that E1 bore O-linked
instead of N-linked glycans. The “peplomeric glycoprotein E2 was
not detectable upon tunicamycin treatment,” indicating its synthesis
was interdicted or its degradation was facilitated by lack of N-linked
glycosylation and was improperly processed (Holmes et al. 1981).
E2 may be analogous to the S-spike glycoprotein. Viral particles
were produced with tunicamycin treatment but were noninfective,
lacking E2, which was required for attachment to viral receptors
on cells, probably analogous ACE2 by today’s knowledge. At that
time, no drug was known to inhibit O-glycosylation, such as α-
benzyl-GalNAc, in use today. Because of these observations, either
N-linked or O-linked glycosylation interference may potentially inter-
dict SARS-Cov2 infectivity.
Tunicamycin was employed in antiviral tests and was very effec-
tive, but it was considered too toxic by most investigators to be
developed as a drug at the concentrations used. However, Banerjee
et al. (2011), in cancer treatment, found a safe concentration of
a purified tunicamycin and dosage in mice (250 μg/kg oral twice
a week for 4 weeks) that inhibited MDA-MB0231 triple negative
breast-cancer tumor formation in live mice, without overt toxicity
and involved the unfolded protein response. Nanoformulations were
effective (Banerjee et al. 2013). Recent articles define the detailed
basis for tunicamycin’s activity (Hakulinen et al. 2017; Yoo et al.
2018). Tunicamycins should be tested now for infectivity assays with
SARS COV2 alone or in combinations with other inhibitors.
Elbein et al. (1982) showed swainsonine, an α-mannosidase
inhibitor, to inhibit processing of oligosaccharides on influenza
viral hemagglutinin, and in 1983 showed its effect on vesicular
stomatitis virus (Kang and Elbein 1983). In 1983, he showed
castanospermine, an α-glucosidase inhibitor, inhibited influenza
hemagglutinin expression (Pan et al. 1983). Both inhibited N-
glycan processing. Tyms et al. (1987) showed castanospermine
and other plant alkaloid glucosidase inhibitors to block HIV
growth. Sunkara et al. (1987) tested castanospermine and 1-
deoxynojirimycin (Duvoglustat) showing anti-retroviral activity.
Dwek et al. (1998) later suggested α-glucosidase inhibitors as
general antiviral agents (Mehta et al. 1998). Chapel et al. (2006)
showed antiviral effects of α-glucosidase inhibitors on hepatitis C
virus. Chang et al. (2013a) reported that iminosugar α-glucosidase
inhibitors related to 1-deoxynojirimycin (that interfered with N-
linked glycan maturation in the calnexin-mediated folding pathway)
were also effective as antivirals for Arenaviridae, Bunyaviridae,
Filoviridae and Flaviviridae including hemorrhagic fever Marburg
and Ebola in mice. 1-Deoxynojirimycin (Duvoglustat) suppresses
postprandial blood glucose and is used for treatment of diabetics
in doses of 20-110 mg/kg (Gao et al. 2016, Tong et al. 2018). Qu
et al. (2011), inhibitors of endoplasmic reticulum α-glucosidases
potently suppress hepatitis C virus virion assembly and release.
Howe et al. (2013) applied similar compounds to HCV and BVDV.
Castanospermine and its O- and N-butyl derivatives were tested in
many viral systems with positive results and FDA approval for type
2 diabetes and Gaucher’s treatments as described below. Off-label,
repurposing treatments for COVID19 should be considered.
Celgosivir (6-O-butanoyl castanospermine), an approved α-
glucosidase inhibitor drug for type 2 diabetes and Gaucher’s disease,
inhibits all four Dengue, DENV serotypes (Sayce et al. 2010;
Rathore et al. 2011). “Fluorescence microscopy showed that the
antiviral mechanism of Celgosivir, is in part, due to misfolding
and accumulation of DENV non-structural protein 1 (NS1) in the
endoplasmic reticulum” (Lachmann 2003). Moreover, Celgosivir
modulates the host’s unfolded protein response (UPR) for its antiviral
action. Significantly, Celgosivir is effective in lethal challenge mouse
models that recapitulate primary or secondary antibody-dependent
enhanced DENV infection. Celgosivir-treated mice showed enhanced
survival, reduced viremia and robust immune response, as reflected
by serum cytokine analysis. Importantly, survival increased even
after treatment was delayed till 2 days post-infection.” (Rathore
et al. 2011). Together, this suggests that Celgosivir, which has been
clinically determined to be safe in humans, may be a valuable
candidate for clinical testing in COVID19 patients. (Ibid).
Safety
Celgosivir has passed safety studies in humans (Sels et al. 1999;
Rathore et al. 2011). N-butyl-deoxynojirimycin (Miglustat) has been
approved for clinical use since 2002 for Gaucher’s disease (Cox et al.
2000; Lachmann 2003), after tests in 2000 to show its activity was
to decrease substrate biosynthesis. This safety data suggests that both
should be investigated repurposed off-label for COVID19 infectivity,
since safety, PK and dosage has already been established. Also,
long-term, 24-month studies of Miglustat have established safety
and efficacy (Pastores et al. 2005), where COVID19 treatment may
require very brief application. Chang et al. (2013b) and Pérez-García
et al. (2017) reviewed and recommended the use of ER glycosylation
inhibitors as potential targets for viral therapeutics. Main side effects
were GI, manageable by diet and anti-propulsives. Duvoglustat, (1-
deoxymannojirimycin) (Fuhrmann et al. 1984) amphomycin and
related compounds should also be tested. Considering the seriousness
of this pandemic, researchers with access to these and other glycosy-
lation inhibitors should collaborate with virology labs that can test
the infectivity cycle of SARS COV2.
Following Okayama’s earlier work (1973), Schwartz et al. (1974)
showed stimulation of synthesis of free chondroitin sulfate chains
by ß-D-xylosides in cultured cells. Esko and Montgomery (1995),
following Okayama’s and Schwartz’s earlier work, described xyloside
“primers” of glycans that could be employed in tissue culture to
prevent sugars from attaching to proteins, proteoglycans and glycol-
ipids. They found ß-D-xylosides initiate glycosaminoglycan (GAG)
synthesis by substituting for endogenous xylosylated core proteins.
Xylosides will also prime oligosaccharides that resemble glycol-
ipids. N-acetyl-α-D-galactosaminides initiate O-linked oligosaccha-
ride synthesis found on mucins and other glycoproteins and can
be used to disrupt O-glycosylation. Disaccharides, (e.g. peracety-
lated N-acetyllactosaminide), can act as primers. Competing with
endogenous substrates, they interdict proteoglycan and glycoprotein
glycosylation. Esko used acetylated xylose derivatives where PNP-Xyl
treatment decreased heparan sulfate expression on the cell surface
of Syndecan 4 cells and abrogated the HCV transmission in a
concentration-dependent manner (Shieh et al. 1992; Fritz et al. 1994;
Fritz and Esko 2001). Xylosides and thioxylosides should be tested
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E-selectin/ligand interdiction for inflammation
in the ARDS symptoms in COVID19
E-selectin is a key to the first step in inflammation where E-selectin
ligand Sialyl LeX binds E-selectin on capillary endothelium for
neutrophil extravasation. Mulligan et al. (1993) early showed in
a mouse lung inflammation model of ARDS that oligosaccharides
containing Sialyl LeX inhibited neutrophils from causing the pneu-
monic symptoms. Glycomimetics, Inc., under John Magnani’s scien-
tific direction, has developed pan-selectin inhibitors and follow-on
compounds that may also be effective in interdiction of the ARDS
pathology (Chang et al. 2010). Magnani et al. developed a potent
anti-inflammatory Sialyl LeX analog that interdicted inflammation
in sickle cell anemia (Chang et al. 2010), and this and follow-on
compounds from glycomimetics could be employed to test COVID19
lung and cardiac inflammation. Neelamegham, Matta et al. (Wang
et al. 2018) reported using thioglycoside N-glycosylation decoys to
hijack E-selectin ligand glycosylation, such that neutrophils treated
with acetylated GlcNAc-S-NAP are 90% inhibited in rolling and teth-
ering, and 90% inhibited in extravasation in a mouse ex-vivo model.
Experiments with lung inflammation mouse models such as used by
Mulligan et al. (1993) should be pursued toward finding drugs for
the deadly pneumonic phase of COVID19 that is responsible for most
fatalities.
It seems a reasonable approach that interfering with host gly-
cosylation systems hijacked by SARS COV2, plus interfering with
the ACE2 receptor glycosylation may combine to 1) interdict infec-
tivity and 2) glycosylation interference with Sialyl LeX can inhibit
E-selectin-based inflammatory responses, mitigating the Covid19
ARDS pathology. Important here is that decoys of glycosylation
address the host enzyme systems; therefore, the virus cannot perform
a simple mutation to overcome the interdiction, as in vaccines, like
influenza. In addition, several of the compounds are FDA approved
for other indications, which could be repurposed and tested off-label.
Heparinoid efficacy
Coagulopathies and heparin treatment are the subject of several
articles regarding the pathology of COVID19 (Becker 2020; Por-
fidia and Pola 2020), and heparan sulfate derivatives and sulfated
oligosaccharides appear from several laboratories to play a role in
the binding of spike protein to the ACE2 receptor (Clausen et al.
2020; Kim et al. 2020; Kwon et al. 2020; Mycroft-West et al. 2020;
Tandon et al. 2020; Zhang et al. 2020). Thus, heparan sulfate derived
or sulfated nonanticoagulant and anticoagulant oligosaccharides and
derivatives may be effective interdictors of both viral infectivity and
coagulopathies, and FDA-approved heparinoid products should be
considered for repurposing for COVID19.
Summary
Glycobiologists with access to any of the compounds mentioned
herein or related to glycosylation interdictors are encouraged to
send their samples for testing to virology labs conducting SARS
COV2/ACE2-binding studies, spike glycoprotein fusion tests, or
infectivity assays. Repurposing of already approved drugs, and testing
others with low toxicity may uncover other avenues from a solid
glycobiology antiviral background for a much-needed development
of COVID19 therapeutics. There are also outstanding opportunities
for selectin anti-inflammatory and heparinoid anticoagulation
approaches for COVID19 ARDS.
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